Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations-Reference-Cited by-同舟云学术

Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations

Published:2021-09-15 Issue: Volume:28 Page:
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Garmpis Nikolaos¹,Damaskos Christos²,Garmpi Anna³,Nonni Afroditi⁴,Georgakopoulou Vasiliki E.⁵,Antoniou Efstathios¹,Schizas Dimitrios¹,Sarantis Panagiotis⁶,Patsouras Alexandros⁷,Syllaios Athanasios⁸,Vallilas Christos⁶,Koustas Evangelos⁶,Kontzoglou Konstantinos¹,Trakas Nikolaos⁹,Dimitroulis Dimitrios¹

Affiliation:

1. Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

2. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece

3. First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

4. First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

5. Department of Pulmonology, Laiko General Hospital, Athens, Greece

6. Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece

7. Renal Transplantation Unit, Laiko General Hospital, Athens, Greece

8. First Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

9. Department of Biochemistry, Sismanogleio Hospital, Athens, Greece

Abstract

: Colorectal cancer (CRC) comprises a heterogeneous group of gastrointestinal tract tumors. It is a multifactorial disease, and a plethora of distinct factors are involved in its pathogenesis and pathophysiology. The development of CRC is not limited to genetic changes, but epigenetic and environmental factors are also involved. Among the epigenetic factors, histone deacetylases (HDACs), a group of epigenetic enzymes that regulate gene expression, have been reported to be over-expressed in CRC. HDACs and their inhibitors seem to play an important role in the molecular pathophysiology of CRC. The aim of this review was to define the role of HDAC inhibitors as potential anticancer agents against CRC.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nano-energy interference: A novel strategy for blunting tumor adaptation and metastasis;Materials Today Bio;2024-04

2. MS275 induces tumor immunosuppression by up-regulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer;2024-03-22

3. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05

4. Synthetic derivatives of natural cinnamic acids as potential anti‐colorectal cancer agents;Chemical Biology & Drug Design;2023-12-18

5. Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth;Cell Death & Disease;2023-12-07